Rentschler Forms Strategic Alliance for Protein-Based Formulations
By

By
Rentschler Biotechnologie, a Laupheim, Germany-headquartered contract development and manufacturing organization (CDMO) for biopharmaceuticals, has formed a strategic alliance with Leukocare, a Martinsried, Germany-headquartered drug formulation company focused on protein therapeutics,…

AMRI in Drug Discovery Alliance
By

By
AMRI, an Albany, New York-based contract research and manufacturing organization, has formed an alliance with Bruker Daltonics, a Billerica, Massachusetts-based manufacturer of scientific instruments, and HighRes Biosolutions, a Woburn, Massachusetts-based manufacturer…

Piramal to Acquire Mallinckrodt Intrathecal Portfolio
By

By
Mallinckrodt, a specialty pharmaceutical company has agreed to sell its intrathecal therapy business to Piramal Critical Care, the UK-based subsidiary of Piramal Enterprises that specializes in anesthesia, for approximately $203 million.…

AbbVie, Merck & Co., Pfizer, and Teva Lead Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring news from AbbVie, Merck & Co., Perrigo, Pfizer, and Teva. Editor’s…

BMS, Endo, Merck & Co., and Sanofi Lead Drug Approval News
By

By
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from BMS, Endo, Merck & Co., and Sanofi. Editor’s Note: This article is updated on a continuous…

Novartis Withdraws European Application for Biosimilar
By

By
Novartis has withdrawn its marketing authorization application (MMA) with the European Medicines Agency (EMA) for its biosimilar candidate to Amgen’s Neulasta (pegfilgrastim), a drug for inducing white blood cell production…

Allergan Completes $2.9-Billion Acquisition of Regenerative Meds Company
By

By
Allergan has successfully completed the acquisition of LifeCell Corporation, the regenerative medicines business of Acelity, a San Antonio, Texas-headquartered wound care and regenerative medicines company, for approximately $2.9 billion in…

Japanese Court Rules in Favor of Lilly’s Vitamin Regimen Patent
By

By
The Japan Intellectual Property High Court has ruled in favor of Eli Lilly and Company and has confirmed the decisions of the Japan Patent Office that invalidated trials initiated by…

Astellas Licenses Ear-Care Drug Program
By

By
Astellas Pharma has executed a license agreement for an exclusive worldwide license to an ear-care program with Auration Biotech, a San Mateo, California-based privately held biotechnology company that specializes in…

Portola Sells Rights to Blood Coagulant Drug
By

By
Portola Pharmaceuticals, a South San Francisco, California-based biopharmaceutical company focused on the field of thrombosis and other hematologic diseases, has signed a $150-million royalty agreement with HealthCare Royalty Partners (HCR),…